Tags

Type your tag names separated by a space and hit enter

Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Drugs. 2015 Apr; 75(5):533-42.D

Abstract

Sucroferric oxyhydroxide (Velphoro®), an iron-based oral phosphate binder, is available for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In a pivotal phase III trial, sucroferric oxyhydroxide 1000-3000 mg/day for 24 weeks was noninferior to sevelamer carbonate 4800-14,400 mg/day with regard to lowering serum phosphorus levels. Additionally, sucroferric oxyhydroxide at maintenance dosages was significantly more effective than low dosage sucroferric oxyhydroxide (250 mg/day) with regard to maintaining controlled serum phosphorus levels during weeks 24-27 of treatment. Sucroferric oxyhydroxide had a numerically lower mean daily pill burden and better treatment adherence than sevelamer carbonate. Treatment with sucroferric oxyhydroxide was generally well tolerated over 24 weeks' treatment, with the most frequently reported treatment-emergent adverse events being mild, transient diarrhoea and discoloured faeces. In a 28-week extension study, the efficacy and tolerability profile of sucroferric oxyhydroxide remained similar to sevelamer carbonate for up to 52 weeks. In conclusion, sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence.

Authors+Show Affiliations

Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25761962

Citation

Greig, Sarah L., and Greg L. Plosker. "Sucroferric Oxyhydroxide: a Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis." Drugs, vol. 75, no. 5, 2015, pp. 533-42.
Greig SL, Plosker GL. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. Drugs. 2015;75(5):533-42.
Greig, S. L., & Plosker, G. L. (2015). Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. Drugs, 75(5), 533-42. https://doi.org/10.1007/s40265-015-0366-1
Greig SL, Plosker GL. Sucroferric Oxyhydroxide: a Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis. Drugs. 2015;75(5):533-42. PubMed PMID: 25761962.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. AU - Greig,Sarah L, AU - Plosker,Greg L, PY - 2015/3/13/entrez PY - 2015/3/13/pubmed PY - 2015/7/22/medline SP - 533 EP - 42 JF - Drugs JO - Drugs VL - 75 IS - 5 N2 - Sucroferric oxyhydroxide (Velphoro®), an iron-based oral phosphate binder, is available for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In a pivotal phase III trial, sucroferric oxyhydroxide 1000-3000 mg/day for 24 weeks was noninferior to sevelamer carbonate 4800-14,400 mg/day with regard to lowering serum phosphorus levels. Additionally, sucroferric oxyhydroxide at maintenance dosages was significantly more effective than low dosage sucroferric oxyhydroxide (250 mg/day) with regard to maintaining controlled serum phosphorus levels during weeks 24-27 of treatment. Sucroferric oxyhydroxide had a numerically lower mean daily pill burden and better treatment adherence than sevelamer carbonate. Treatment with sucroferric oxyhydroxide was generally well tolerated over 24 weeks' treatment, with the most frequently reported treatment-emergent adverse events being mild, transient diarrhoea and discoloured faeces. In a 28-week extension study, the efficacy and tolerability profile of sucroferric oxyhydroxide remained similar to sevelamer carbonate for up to 52 weeks. In conclusion, sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/25761962/Sucroferric_oxyhydroxide:_a_review_in_hyperphosphataemia_in_chronic_kidney_disease_patients_undergoing_dialysis_ L2 - https://dx.doi.org/10.1007/s40265-015-0366-1 DB - PRIME DP - Unbound Medicine ER -